Synthomer Share Discussion Threads

[thorpematt] 28/10/2021 10:45

I recently bought in here. I thought it looked very solid and far too cheap on any measure. The chart appeared to read oversold to me too. The market obviously likes the aquisition despite the fundraising.

[kinwah] 28/10/2021 09:31

Historically SYNT's acquisitions have always provided a boost to earnings in the medium term. The timing looks good as the nitrile super profits will be coming to an end fairly soon. I can see the shares hitting £6 some time next year.

[madjak] 28/10/2021 07:17

Acquisition http://otp.investis.com/generic/regulatory-story.aspx?cid=476&newsid=1521273 Share Placing http://otp.investis.com/generic/regulatory-story.aspx?cid=476&newsid=1521275

[scooper72] 07/9/2021 13:43

Why is it not a surprise?

[philanderer] 07/9/2021 13:16

Strike HTTPS://actu.fr/normandie/sandouville_76660/nouveau-debrayage-de-plusieurs-dizaines-de-salaries-de-synthomer-pres-du-havre_44594676.html

[login] 23/8/2021 18:59

Hound partners have increased their short. Not surprising really

[philanderer] 23/8/2021 10:15

UBS RAISES SYNTHOMER PRICE TARGET TO 550 (530) PENCE - 'NEUTRAL'

[rbewes] 09/8/2021 19:17

Your wife has a big future unless taken out by a predator?

[james dean] 09/8/2021 18:11

p so is the wife I'm pleased to say. .

[cardinal3] 09/8/2021 17:14

Brilliant results and positive forecast. Also note the deleveraging which gives scope for investment/acquisitions. I think this is a company which has a big future unless taken out by a predator.

[philanderer] 06/8/2021 20:00

Agree maurice, holding on to all mine.

[mauricemonkey] 06/8/2021 18:35

I’d be bothered if that was all they made, but it isn’t. PE(F) of 10 seems low and a not terrible divi while I await the rerate. I think Berenberg have got this wrong. Time will tell obviously.

[philanderer] 06/8/2021 17:15

(Sharecast News) - London's FTSE 250 was down 0.2% at 23,468.78 in afternoon trade on Friday. Synthomer was knocked lower by a downgrade to 'hold' from 'buy' at Berenberg. The bank said that while welcome, Synthomer's pre-released first-half results probably mark the end of the organic upgrade cycle. "For all management's work in upgrading the portfolio and reducing leverage, the stock appears to be entering a precarious phase for industrial names: increasing amounts of capex directed towards a level at which there is declining return on capital employed (nitrile latex). "Given two-year valuation is no longer low enough to make a compelling case for shares, we downgrade to hold with a new price target of 550p."

[philanderer] 06/8/2021 10:13

login, who has upgraded ? thanks

[login] 06/8/2021 09:36

Just upgraded our target price to 727

[farnesbarnes] 06/8/2021 09:21

The 342k sell has been matched with a 350k buy.

[philanderer] 06/8/2021 09:07

Some serious dumping going on ... 1 million + printed already.

[philanderer] 06/8/2021 08:49

Downgrade it is then.. BERENBERG CUTS SYNTHOMER TO 'HOLD' (BUY) - PRICE TARGET 550 (560) PENCE

[philanderer] 05/8/2021 23:26

Synthomer storms ahead Synthomer proves, if proof were needed, that even nitrile latex companies can have their day. HTTPS://www.investorschronicle.co.uk/news/2021/08/05/synthomer-storms-ahead/

[deanowls] 05/8/2021 20:54

I’ve had three COVID tests in the last eeek to travel. Every time a new pair of plastic disposable gloves. Use will continue for some time yet.

[philanderer] 05/8/2021 18:15

Canaccord put out a 'buy', tp 750p , on monday this week. ---------------- Canaccord ups price target on Synthomer Analysts at Canaccord Genuity raised their target price on chemicals outfit Synthomer from 700.0p to 750.0p on Monday, citing a fourth upgrade to full-year guidance. Synthomer announced a further update to its guidance for 2021 underlying earnings in July, EBITDA, now to "above £500.0m" from previous estimates of over £450.0m. The Canadian bank pointed out that the source of the further upgrade appeared to be broad-based. "Overall, we now expect net EPS to be up more than 150% this year on unit margins (€/ton) roughly doubling, with the overwhelming majority of that improvement coming from the nitrile business," said Canaccord. "Whilst normalisation is likely to come in the medium term, we continue to see super-normal profits in nitrile through 2022E, due both to the direct and ongoing impacts of the pandemic on PPE demand, but also the indirect increase in healthcare workers' (and others') demand for greater protection." As a result, Canaccord, which also stood by its 'buy' rating on the stock, upgraded 2022/23 EPS estimates by roughly 8% but also highlighted "increased optionality" at Synthomer, whether from the rapid debt reduction or opportunity for further expansion. [...]